Survival in Oligometastatic Prostate Cancer—A New Dawn or the Will Rogers Phenomenon?
- 1 February 2020
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 6 (2) , 185-186
Abstract
This Viewpoint describes potential improvements in classification of cases of oligometastatic prostate cancer and resulting research opportunities.Keywords
This publication has 7 references indexed in Scilit:
- Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trialThe Lancet, 2018
- Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II TrialJournal of Clinical Oncology, 2018
- Change in prostate cancer presentation coinciding with USPSTF screening recommendations at a community-based urology practiceUrologic Oncology: Seminars and Original Investigations, 2017
- Sensitivity, Specificity, and Predictors of Positive 68 Ga–Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysisEuropean Urology, 2016
- Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysisSkeletal Radiology, 2014
- Oligometastases revisitedNature Reviews Clinical Oncology, 2011
- Prostate Cancer and the Will Rogers PhenomenonJNCI: Journal of the National Cancer Institute, 2005